Elizabeth M. Hill, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 3B38
- Bethesda, MD 20892
- 240-889-5377
- Elizabeth.Hill@nih.gov
RESEARCH SUMMARY
Dr. Hill is an Assistant Research Physician specializing in the diagnosis and treatment of plasma cell malignancies including Multiple Myeloma and Smoldering Myeloma. She leads the Multiple Myeloma clinical team within the Lymphoid Malignancies Branch (LYMB) of the Center for Cancer Research. Her research interests include evaluating treatment interventions for high-risk smoldering myeloma and novel treatment approaches for relapsed and/or refractory multiple myeloma.
Areas of Expertise
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Clinical Trials
Research
Dr. Hill designs and conducts clinical trials for patients with plasma cell malignancies. She is interested in the outcomes of treatment for patients with smoldering myeloma and identifying efficacious and well tolerated combinations of therapy for this asymptomatic patient population. She also works closely with the scientists in the laboratory helping to translate their discoveries into clinical trials for patients with advanced plasma cell disorders. Through multiple collaborations with NIH scientists, her translational work examines how the immune system is affected by myeloma, changes with treatment, and how it may be used as a predictor of response.
Biography
Elizabeth M. Hill, M.D.
Dr. Hill earned a Bachelor of Science in Biology from The George Washington University in 2009. She was a scholar in the quantitative and natural sciences and was granted a Howard Hughes research fellowship to advance her studies in molecular biology. She received her M.D from Georgetown University School of Medicine in 2013 and completed her Internal Medicine Residency at Georgetown University Hospital in 2016. She served as a Chief Internal Medicine Resident from 2016-2017 then completed her fellowship in Hematology and Oncology at the NIH in 2020. After fellowship she served as a medical officer with the myeloma team in the Division of Hematologic Malignancies II at the U.S. Food and Drug Administration as well as a clinical collaborator with the lymphoid malignancies branch at NIH. In 2022 she returned to the NIH to lead the clinical myeloma program as an Assistant Research Physician.
